ArticleIndian journal of ophthalmology2026
Clinical outcomes of slow-coagulation continuous wave diode transscleral cyclophotocoagulation laser for treatment of refractory glaucoma.
Article in Indian journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the short-term safety and efficacy of slow-coagulation trans-scleral cyclophotocoagulation (SC-TSCPC) in patients with refractory glaucoma.
methodsA retrospective study was done on 140 patients (144 eyes) with a diagnosis of refractory glaucoma and vision more than 2/60 with a minimum follow-up of 6 months. All patients underwent SC-TSCPC (800-milliwatt power and 4 seconds duration). The primary outcome measure was surgical success defined as an intraocular pressure (IOP) from 6 to 21 mmHg or ≥20% IOP reduction from the baseline value, no reoperation for glaucoma, and no loss of light perception vision. Secondary outcome measures include percentage of IOP reduction, glaucoma medications, visual acuity, and complications.
resultsMean IOP decreased from 40.97 ± 12.00 mmHg preoperatively to 19.31 ± 9.91 mmHg (mean percentage IOP reduction = 52.9%) at 6 months postoperatively ( P < 0.0001). The number of glaucoma medications also dropped from 3.0 ± 0.89 at baseline to 2.0 ± 1.4 at 6 months ( P = 0.0003). No significant deterioration in visual acuity was observed during 6 months follow-up ( P < 0.0001). The cumulative probabilities of success at 1, 3, and 6 months were 86.1%, 77.4%, and 66.64%, respectively. Eyes with baseline IOP >30 mmHg demonstrated lower success rates, higher postoperative complications, and greater need for additional glaucoma interventions compared with eyes having baseline IOP <30 mmHg. The most common complications observed were uncontrolled IOP and anterior chamber inflammation. Endophthalmitis and retinal detachment were seen in one patient at 6-month follow-up.
conclusionSC-TSCPC may serve as a useful adjunct or temporizing procedure in selected refractory glaucoma patients who are at high risk for invasive glaucoma surgery. Patients with high preoperative IOP required more surgical interventions and also had more complications warranting individualized laser energy settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.